

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

### **Listing of Claims:**

Claim 1 (Original) A method of measuring the accumulation of anti-tumor drugs by solid tumors comprising,

administering an anti-tumor drug labeled with a positron-emitter to a patient having a solid tumor, and

imaging at least part of the patient using PET.

Claim 2 (Original) The method according to claim 1, wherein the solid tumor is selected from the group consisting of breast, lung, ovarian, gastrointestinal, prostate, sarcoma and head and neck tumors.

Claim 3 (Currently Amended) The method of claim 1, wherein the labeled drug is at least one drug selected from the group consisting of  $^{11}\text{C}$ -paclitaxel,  $^{11}\text{C}$ -docetaxel,  $^{11}\text{C}$ -epirubicin,  $^{11}\text{C}$ -mitoxantrone,  $^{11}\text{C}$ -topotecan, and a drug for the treatment of solid tumors taxane that has been radiolabeled.

Claim 4 (Original) A method of determining the efficacy of an anti-tumor drug for treating solid tumors comprising:

administering an anti-tumor drug labeled with a positron-emitter to a patient having a solid tumor; and

imaging at least part of the patient by PET to measure accumulation of the labeled anti-tumor drug.

Claim 5 (Original) The method according to claim 4, wherein the labeled anti-tumor drug is administered prior to a course of treatment of the patent.

Claim 6 (Original) The method of claim 4, wherein the labeled anti-tumor drug is administered during the course of treatment of the patent.

Claim 7 (Currently Amended) The method of claim 4, wherein the labeled drug is at least one drug selected from the group consisting of  $^{11}\text{C}$ -paclitaxel,  $^{11}\text{C}$ -docetaxel,  $^{11}\text{C}$ -doxorubicin,  $^{11}\text{C}$ -epirubicin,  $^{11}\text{C}$ -mitoxantrone,  $^{11}\text{C}$ -topotecan, and a drug for the treatment of solid tumors taxane that has been radiolabeled.

Claim 8 (Original) A method of measuring the effectiveness of modulators of cellular accumulation mechanisms in tumors comprising:

administering an anti-tumor drug labeled with a positron-emitter to a patient;

administering a modulator to the patient, and

imaging at least part of the patient by PET to measure accumulation of the labeled anti-tumor drug.

Claim 9 (Original) The method of claim 8, wherein the accumulation of labeled anti-tumor drug is measured before and after administering the modulator to the patient and the levels of anti-tumor drug accumulation before and after administering the modulator are compared.

Claim 10 (Original) The method of claim 8, wherein modulator affects an efflux mechanism.

Claim 11 (Original) The method of claim 8, wherein modulator affects an influx mechanism.

Claim 12 (Currently Amended) The method of claim 8, wherein the labeled drug is at least one drug selected from the group consisting of  $^{11}\text{C}$ -paclitaxel,  $^{11}\text{C}$ -docetaxel,  $^{11}\text{C}$ -doxorubicin,  $^{11}\text{C}$ -epirubicin,  $^{11}\text{C}$ -mitoxantrone,  $^{11}\text{C}$ -topotecan, and a taxane drug for the treatment of solid tumors that has been radiolabeled.

Claim 13 (Original) A method for measuring the effectiveness of a combination of anti-tumor drugs comprising:

administering more than one anti-tumor drug to a patient having a solid tumor, wherein at least one of said anti-tumor drugs is labeled with a positron-emitter, and

imaging at least part of the patient by PET to measure accumulation of the labeled anti-tumor drug.

Claim 14 (Original) The method of claim 13, wherein two anti-tumor drugs are administered to the patient.

Claim 15 (Original) The method of claim 13, wherein one of said anti-tumor drugs is labeled with a positron-emitter.


Claim 16 (Original) The method of claim 13, wherein two of said anti-tumor drugs are each labeled with a positron-emitter.

Claim 17 (Original) The method claim 13, wherein a first anti-tumor drug and a second anti-tumor drug are administered simultaneously.

Claim 18 (Original) The method claim 13, wherein a first anti-tumor drug and a second anti-tumor drug are administered sequentially.

Claim 19 (Currently Amended) The method of claim 13, wherein the labeled drug is at least one drug selected from the group consisting of  $^{11}\text{C}$ -paclitaxel,  $^{11}\text{C}$ -docetaxel,  $^{11}\text{C}$ -doxorubicin,  $^{11}\text{C}$ -epirubicin,  $^{11}\text{C}$ -mitoxantrone,  $^{11}\text{C}$ -topotecan, and a taxane drug for the treatment of solid tumors that has been radiolabeled.

Claim 20 (Original) A compound having the formula:



wherein:

$R_1$  is selected from the group consisting of H, acetate and  $^{11}\text{C}$ -acetate;

$R_2$  is selected from the group of acetate and  $^{11}\text{C}$ -acetate;

$R_3$  is selected from the group consisting of benzoyl,  $^{11}\text{C}$ -benzoyl,  $-\text{CO}_2\text{C}(\text{CH}_3)_3$  and  $^{-11}\text{CO}_2\text{C}(\text{CH}_3)_3$ ; and

$R_4$  selected from the group consisting of benzoyl  $^{11}\text{C}$ -benzoyl; and

wherein the compound contains at least one atom of  $^{11}\text{C}$ .

Claim 21 (Original) A compound according to claim 20, wherein  $R_1$  is  $^{11}\text{C}$ -acetate,  $R_2$  is acetate,  $R_3$  is benzoyl and  $R_4$  is benzoyl.

Claim 22 (Original) A compound according to claim 20, wherein  $R_1$  is acetate,  $R_2$  is  $^{11}\text{C}$ -acetate and  $R_3$  is benzoyl and  $R_4$  is benzoyl.

Claim 23 (Original) A compound according to claim 20, wherein R<sub>1</sub> and R<sub>2</sub> are acetate and R<sub>3</sub> is <sup>11</sup>C- benzoyl and R<sub>4</sub> is benzoyl.

Claim 24 (Original) A compound according to claim 20, wherein R<sub>1</sub> and R<sub>2</sub> are acetate, R<sub>3</sub> is benzoyl and R<sub>4</sub> is <sup>11</sup>C-benzoyl

Claim 25 (Withdrawn) A compound according to claim 20, wherein R<sub>1</sub> is H, R<sub>2</sub> is acetate, R<sub>3</sub> is -<sup>11</sup>CO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>. and R<sub>4</sub> is benzoyl.

Claim 26 (Withdrawn) A compound according to claim 20, wherein R<sub>1</sub> is H, R<sub>2</sub> is <sup>11</sup>C-acetate, R<sub>3</sub> is CO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub> and R<sub>4</sub> is benzoyl

Claim 27 (Withdrawn) A compound according to claim 20, wherein R<sub>1</sub> is H, R<sub>2</sub> is acetate, R<sub>3</sub> is

- CO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub> and R<sub>4</sub> is <sup>11</sup>C-benzoyl.

Claim 28 (Original) A method of synthesizing the compound according to claim 20, comprising the steps of:

reacting 10-deacetylpaclitaxel with a chlorotrialkylsilane to yield a protected deacetylpaclitaxel;

reacting the protected deacetylpaclitaxel with <sup>11</sup>C-acetyl chloride to yield a radio-labeled silyl protected deacetylpaclitaxel;

removing the protecting groups, and

isolating <sup>11</sup>C-paclitaxel.

Claim 29 (Original) A method of synthesizing the compound according to claim 20, comprising the steps of:

reacting paclitaxel primary amine with  $^{11}\text{C}$ -benzoyl chloride, and  
isolating  $^{11}\text{C}$ -paclitaxel.

Claim 30 (Withdrawn) A method of synthesizing the compound according to claim 20,  
comprising the steps of:

reacting docetaxel primary amine with  $^{11}\text{C}$ -di-tert-butyl dicarbonate, and  
isolating  $^{11}\text{C}$ -docetaxel.

Claim 31 (Withdrawn) A method of synthesizing the compound according to claim 20,  
comprising the steps of:

reacting paclitaxel primary amine with  $^{11}\text{C}$ -di-tert-butyl dicarbonate to give  
 $^{11}\text{C}$ -10-acetyldocetaxel; and

reacting the  $^{11}\text{C}$ -10-acetyldocetaxel with hydrogen peroxide to give  $^{11}\text{C}$ -docetaxel.

Claims 32-40 (Canceled)


Claim 41 (New) A method of measuring the accumulation of anti-tumor drugs by solid  
tumors comprising,

administering an anti-tumor drug labeled with a positron-emitter to a patient having a  
solid tumor, and

imaging at least part of the patient using PET;

wherein said anti-tumor drug labeled with a positron-emitter comprises an anti-tumor  
drug having a naturally occurring atom replaced with a radioisotope of the same element.

Claim 42 (New) The method of claim 41, wherein the anti-tumor drug labeled with a positron-emitter comprises a compound having the formula:



wherein:

$R_1$  is selected from the group consisting of H and acetate;

$R_2$  is acetate;

$R_3$  is selected from the group consisting of benzoyl and  $-\text{CO}_2\text{C}(\text{CH}_3)_3$ ; and

$R_4$  is benzoyl,

wherein the compound contains at least one atom of  $^{11}\text{C}$ .

Claim 43 (New) The method of claim 41, wherein  $R_1$  is  $^{11}\text{C}$ -acetate,  $R_2$  is acetate,  $R_3$  is benzoyl and  $R_4$  is benzoyl.

Claim 44 (New) The method of claim 41, wherein  $R_1$  is acetate,  $R_2$  is  $^{11}\text{C}$ -acetate and  $R_3$  is benzoyl and  $R_4$  is benzoyl.

Claim 45 (New) The method of claim 41, wherein  $R_1$  and  $R_2$  are acetate and  $R_3$  is  $^{11}\text{C}$ -benzoyl and  $R_4$  is benzoyl.

Claim 46 (New) The method of claim 41, wherein  $R_1$  and  $R_2$  are acetate,  $R_3$  is benzoyl and  $R_4$  is  $^{11}\text{C}$ -benzoyl.

Claim 47 (New) The method of claim 41, wherein  $R_1$  is H,  $R_2$  is acetate,  $R_3$  is  $^{11}\text{CO}_2\text{C}(\text{CH}_3)_3$ , and  $R_4$  is benzoyl.

Claim 48 (New) The method of claim 41, wherein  $R_1$  is H,  $R_2$  is  $^{11}\text{C}$ -acetate,  $R_3$  is  $\text{CO}_2\text{C}(\text{CH}_3)_3$  and  $R_4$  is benzoyl

Claim 49 (New) The method of claim 41, wherein  $R_1$  is H,  $R_2$  is acetate,  $R_3$  is  $\text{CO}_2\text{C}(\text{CH}_3)_3$  and  $R_4$  is  $^{11}\text{C}$ -benzoyl.